These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 28893366)
1. Fidaxomicin reduces early toxin A and B production and sporulation in Clostridium difficilein vitro. Aldape MJ; Packham AE; Heeney DD; Rice SN; Bryant AE; Stevens DL J Med Microbiol; 2017 Oct; 66(10):1393-1399. PubMed ID: 28893366 [TBL] [Abstract][Full Text] [Related]
2. Sub-lethal doses of surotomycin and vancomycin have similar effects on Clostridium difficile virulence factor production in vitro. Aldape MJ; Rice SN; Field KP; Bryant AE; Stevens DL J Med Microbiol; 2018 Dec; 67(12):1689-1697. PubMed ID: 30307842 [TBL] [Abstract][Full Text] [Related]
5. Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile. Aldape MJ; Heeney DD; Bryant AE; Stevens DL J Antimicrob Chemother; 2015 Jan; 70(1):153-9. PubMed ID: 25151204 [TBL] [Abstract][Full Text] [Related]
6. Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production. Chilton CH; Crowther GS; Ashwin H; Longshaw CM; Wilcox MH PLoS One; 2016; 11(8):e0161200. PubMed ID: 27556739 [TBL] [Abstract][Full Text] [Related]
7. In vitro efficacy of sodium selenite in reducing toxin production, spore outgrowth and antibiotic resistance in hypervirulent Clostridium difficile. Pellissery AJ; Vinayamohan PG; Yin HB; Mooyottu S; Venkitanarayanan K J Med Microbiol; 2019 Jul; 68(7):1118-1128. PubMed ID: 31172910 [TBL] [Abstract][Full Text] [Related]
8. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China. Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926 [TBL] [Abstract][Full Text] [Related]
9. Fidaxomicin for the treatment of Clostridium difficile infections. Whitman CB; Czosnowski QA Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930 [TBL] [Abstract][Full Text] [Related]
10. Strain-Dependent RstA Regulation of Clostridioides difficile Toxin Production and Sporulation. Edwards AN; Krall EG; McBride SM J Bacteriol; 2020 Jan; 202(2):. PubMed ID: 31659010 [TBL] [Abstract][Full Text] [Related]
11. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Thabit AK; Alam MJ; Khaleduzzaman M; Garey KW; Nicolau DP Ann Clin Microbiol Antimicrob; 2016 Apr; 15():22. PubMed ID: 27071986 [TBL] [Abstract][Full Text] [Related]
12. Time-kill kinetics of cadazolid and comparator antibacterial agents against different ribotypes of Clostridium difficile. Skinner K; Birchall S; Corbett D; Thommes P; Locher HH J Med Microbiol; 2018 Sep; 67(9):1402-1409. PubMed ID: 30052178 [TBL] [Abstract][Full Text] [Related]
13. [Antimicrobial profile and clinical evidence of fidaxomicin (Dafclir Takeda S; Miki T Nihon Yakurigaku Zasshi; 2019; 154(4):217-229. PubMed ID: 31597902 [TBL] [Abstract][Full Text] [Related]
14. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Crawford T; Huesgen E; Danziger L Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025 [TBL] [Abstract][Full Text] [Related]
15. Subinhibitory concentrations of LFF571 reduce toxin production by Clostridium difficile. Sachdeva M; Leeds JA Antimicrob Agents Chemother; 2015 Feb; 59(2):1252-7. PubMed ID: 25512411 [TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. Ochsner UA; Bell SJ; O'Leary AL; Hoang T; Stone KC; Young CL; Critchley IA; Janjic N J Antimicrob Chemother; 2009 May; 63(5):964-71. PubMed ID: 19251726 [TBL] [Abstract][Full Text] [Related]
17. Clostridium difficile and the disease it causes. Norén T Methods Mol Biol; 2010; 646():9-35. PubMed ID: 20597000 [TBL] [Abstract][Full Text] [Related]
18. U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin. Snydman DR; McDermott LA; Jacobus NV; Thorpe C; Stone S; Jenkins SG; Goldstein EJ; Patel R; Forbes BA; Mirrett S; Johnson S; Gerding DN Antimicrob Agents Chemother; 2015 Oct; 59(10):6437-43. PubMed ID: 26239985 [TBL] [Abstract][Full Text] [Related]
19. Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment. James GA; Chesnel L; Boegli L; deLancey Pulcini E; Fisher S; Stewart PS J Antimicrob Chemother; 2018 Jan; 73(1):102-108. PubMed ID: 29029221 [TBL] [Abstract][Full Text] [Related]
20. Effect of sub-MIC concentrations of metronidazole, vancomycin, clindamycin and linezolid on toxin gene transcription and production in Clostridium difficile. Gerber M; Walch C; Löffler B; Tischendorf K; Reischl U; Ackermann G J Med Microbiol; 2008 Jun; 57(Pt 6):776-783. PubMed ID: 18480337 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]